April 30,Eli LillyAnnounced the Q1 2024 financial report, with global revenue of $8.768 billion, a year-on-year increase of 26%. This performance was mainly driven by the growth in drug sales volume and prices.According to the financial report, the overall sales growth in Q1 was mainly due to Type 2 diabetes drugs.Mounjaro（Tirzepatide, $1.807 billion）、Obesity drugsZepbound (Tirzepatide, $517 million)、Breast Cancer DrugsVerzenio(Abemaciclib, $1.05 billion), diabetes drugsJardiance（Empagliflozin, $687 million）The strong push of products such as ..., partially also byTrulicity（Dulaglutide, $1.456 billion) Sales decline offset.Based on this,Eli Lilly's Revenue in China for the Full YearGuidanceIncreased by $2 billion.
Specifically, for the product, the brand of tirzepatide for glycemic controlMounjaro continues to maintain a strong growth rate, After surging more than 10 times to $5.163 billion in 2023, it rose another 217% in Q1 2024, reaching $1.807 billion. Weight loss brandsZepbound inApproved for marketing in early November 2023,In less than two months, nearly $200 million was generated, and the sales for the first quarter of 2024 have already exceeded $500 million. The two products together achieved $23.24 billion in Q1, and breaking through $10 billion by the end of the year is a given. Eli Lilly stated that GLP-1 drugs are already in short supply, and capacity will continue to be expanded in the future, with the largest capacity increase expected in the second half of this year.In April this year, tirzepatideFor the treatment of moderate to severeObstructive Sleep Apnea(OSA) The Phase III SURMOUNT-OSA clinical trial in patients with obesity also achieved positive results. Compared with placebo, tirzepatide...(10mg or 15mg) significantly reduced the Apnea-Hypopnea Index (AHI) in subjects, with the potential to cover a broader population in the future.EngliNet (Jardiance, another blockbuster product from Eli Lilly in the diabetes field, also showed steady growth in revenue for Q1 this year, achieving $687 million in income (+19%), which is inseparable from the market penetration after the expansion of its chronic kidney disease indications.Besides,The heavy-hitter product in the field of oncology, abemaciclib (Verzenio) The market performance is also commendable, with a continuous growth rate driven by clinical breakthroughs in early-stage breast cancer. In Q1, it achieved an impressive 40% growth, reaching 1.05 billion US dollars.Since 2023, it has frequently achieved remarkable results in the fields of obesity, Alzheimer's disease, and other conditions.Significantly raised investors' expectations, and the market value of Eli Lilly soared continuously, frequently hitting new highs.Market Value Record of Pure Pharmaceutical Companies: From $500 Billion in August Last Year After the Half-Year Report to NovemberZepboundFrom $600 billion after receiving FDA approval for weight loss indications to $740 billion today, Eli Lilly and Company achieved this in just 9 months.
In 2024, Eli Lilly and Company will also welcome several key advancements, includingTirzepatide ComparisonSemaglutideHead-to-Head Weight Loss Phase IIISURMOUNT-5 Study Data Readout, Tirzepatide for Heart Failure with Preserved Ejection Fraction (HFpEF) Phase III SUMMIT Study Data Readout and Regulatory Submission, Initiation of a Phase III Study Evaluating GLP-1R/GIPR/GCGR TriagonistretatrutideImpact on Cardiovascular Outcomes in Obese Patients, Alzheimer's Disease DrugsDonanemabWill Face Regulatory Approval......Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
